Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Infectious disease

C&EN En Español

Infografias Periodicas: Breve historia de los medicamentos antivirales

El profesor de química y bloguero de Compound Interest Andy Brunning enumera algunos compuestos notables cuyo objetivo son los virus.

by Andy Brunning, special to C&EN
January 31, 2022 | A version of this story appeared in Volume 100, Issue 4
Advertisement

Most Popular in Biological Chemistry

 

The first column of the infographic details some of the ways in which antivirals can work. These include stopping viruses infecting new cells, stopping copying of virus DNA/RNA, and stopping viral protein breakdown. 

The rest of the graphic shows a timeline of antiviral development. The points highlighted are:
1963: First approved antiviral, idoxuridine 
1977: First systemic antiviral approved, vidarabine 
1981: First highly selective antiviral approved, acyclovir
1987: First antiviral for HIV approved, azidothymidine
1995: First protease inhibitor antiviral approved, saquinavir
1999: Antivirals for influenza approved, oseltamivir (Tamiflu) and zanamivir
2020-21: Antivirals for COVID-19 approved, remdesivir, molnupiravir and nirmatrelvir (Paxlovid) 


Para descargar el pdf de este artículo: cenm.ag/antivirales.

Referencias usadas para crear esta infografía:

Dance, Amber. “The Challenges of Antiviral Treatments.” Knowable Magazine, Feb. 9, 2021.

De Clercq, Erik. “Antivirals: Past, Present and Future.” Biochem. Pharmacol. (2013). DOI: 10.1016/j.bcp.2012.12.011.

De Clercq, Erik. “Antivirals and Antiviral Strategies.” Nat. Rev. Microbiol. (2004). DOI: 10.1038/nrmicro975.

De Clercq, Erik, and Guangdi Li. “Approved Antiviral Drugs over the Past 50 Years.” Clin. Microbiol. Rev. (2016). DOI: 10.1128/CMR.00102-15.

Dolgin, Elie. “The Race for Antiviral Drugs to Beat COVID—and the Next Pandemic.” Nature, April 14, 2021.

Field, Hugh J., and Erik De Clercq. “Antiviral Drugs–a Short History of Their Discovery and Development.” Microbiology Today, May 1 2004.

Una colaboración entre C&EN y Andy Brunning, autor del blog de los famosos gráficos de Compound Interest (compoundchem.com)

Para ver todas otro articulos de C&EN en español, visita cenm.ag/espanol.

La versión original (en inglés) de este artículo se publicó el Jan. 30, 2022, está disponible aquí.

 

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE